Intellectual Property (IP) is important for medical technology companies to attract funding and exits, whether M&A or IPO. Learn best practices and pitfalls to avoid in building strategic patent portfolios to close funding, be competitive, and secure an exit. Investors and executives will also discuss how to position a medtech company to attract investors, collaborators, and partners.
Greenberg Traurig Shareholder David Dykeman will moderate the panel, which will feature Irina Ridley, Chief Legal Officer at Aerin Medical; Jed Cohen, Managing Director, Medical Technology Investment Banking at Raymond James; and Win Rutherfurd, Shareholder at Greenberg Traurig.